{
  "id": "LSB11202",
  "type": "CRS Report Type LSB",
  "typeId": "LSB",
  "number": "LSB11202",
  "active": true,
  "source": "CRSReports.Congress.gov",
  "versions": [
    {
      "source_dir": "crsreports.congress.gov",
      "title": "Xylazine and the Controlled Substances Act: Legal Considerations for Congress",
      "retrieved": "2024-08-01T04:03:50.152795",
      "id": "LSB11202_1_2024-07-19",
      "formats": [
        {
          "filename": "files/2024-07-19_LSB11202_3121db0a5cedda324474de08921bcf9a2d900761.pdf",
          "format": "PDF",
          "url": "https://crsreports.congress.gov/product/pdf/LSB/LSB11202/1",
          "sha1": "3121db0a5cedda324474de08921bcf9a2d900761"
        },
        {
          "format": "HTML",
          "filename": "files/2024-07-19_LSB11202_3121db0a5cedda324474de08921bcf9a2d900761.html"
        }
      ],
      "date": "2024-07-19",
      "summary": null,
      "source": "CRSReports.Congress.gov",
      "typeId": "LSB",
      "active": true,
      "sourceLink": "https://crsreports.congress.gov/product/details?prodcode=LSB11202",
      "type": "CRS Report Type LSB"
    }
  ],
  "topics": []
}